SCHEMBL5225715

SCHEMBL5225715

COc1ccc(NC(=O)c2cc(NS(C)(=O)=O)ccc2NC(=O)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 5/20 0.76
NR1H4 Q96RI1 5/20 0.60
TP53 P04637 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.53
MAPT P10636 3/20 0.53
PPARG P37231 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
PPARA Q07869 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
PPARD Q03181 1/20 0.52
GPBAR1 Q8TDU6 1/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
ALOX15 P16050 1/20 0.52
HPGD P15428 1/20 0.51
MAPK10 P53779 1/20 0.51
TRPV1 Q8NER1 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223117 0.92 F10 (0.64) F10NR1H4TP53SMN1; SMN2MAPT
SCHEMBL5225151 0.89 F10 (0.61) F10NR1H4TP53SMN1; SMN2MAPT
SCHEMBL5225091 0.89 F10 (0.61) F10NR1H4TP53SMN1; SMN2MAPT
SCHEMBL5226610 0.87 NR1H4 (0.60) F10NR1H4TP53SMN1; SMN2PPARG
SCHEMBL5222102 0.85 NR1H4 (0.64) F10NR1H4TP53SMN1; SMN2MAPT
SCHEMBL5225486 0.84 NR1H4 (0.63) F10NR1H4TP53SMN1; SMN2MAPT
SCHEMBL5226932 0.83 NR1H4 (0.57) F10NR1H4TP53SMN1; SMN2MAPT
SCHEMBL5228531 0.82 MEN1 (0.65) F10NR1H4TP53SMN1; SMN2MAPT
SCHEMBL5224050 0.82 NR1H4 (0.60) F10NR1H4TP53SMN1; SMN2MAPT
SCHEMBL5223218 0.81 NR1H4 (0.73) F10NR1H4TP53SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 F10 12/4885NR1H4 2304/4885TP53 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.